Cargando…

Novel Pulmonary Delivery of Drugs for the Management of Atrial Fibrillation

Atrial fibrillation (AF) is the most prevalent cardiac arrhythmia, affecting approximately 335 million patients worldwide. Comprehensive pharmacological treatment of AF includes medications for rate or rhythm control and anticoagulants to reduce the risk of thromboembolism; yet, these agents have si...

Descripción completa

Detalles Bibliográficos
Autores principales:	Islam, Nazrul, Cichero, Emma, Rahman, Shafiqur, Ranasinghe, Isuru
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2022
Materias:	Leading Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9845156/ https://www.ncbi.nlm.nih.gov/pubmed/36255655 http://dx.doi.org/10.1007/s40256-022-00551-8

Ejemplares similares

Novel Drugs for the Treatment of Pulmonary Arterial Hypertension: Where Are We Going?
por: Alamri, Ayedh K., et al.
Publicado: (2023)

Perispinal Delivery of CNS Drugs
por: Tobinick, Edward Lewis
Publicado: (2016)

MicroRNA: Potential Targets for the Development of Novel Drugs?
por: Wu, Wei
Publicado: (2012)

DRUG-SUSCEPTIBILITY PATTERN OF MYCOBACTERIUM TUBERCULOSIS AMONG PULMONARY TUBERCULOSIS PATIENTS IN RIYADH, SAUDI ARABIA
por: Al-Awaidy, Salah T., et al.
Publicado: (1997)

Longitudinal risk of death, hospitalizations for atrial fibrillation, and cardiovascular events following catheter ablation of atrial fibrillation: a cohort study
por: Ngo, Linh, et al.
Publicado: (2022)

In Vivo Delivery of Nucleic Acid-Encoded Monoclonal Antibodies
por: Patel, Ami, et al.
Publicado: (2020)

Emerging Technologies for Delivery of Biotherapeutics and Gene Therapy Across the Blood–Brain Barrier
por: Stanimirovic, Danica B., et al.
Publicado: (2018)

Drugs in Development for Malaria
por: Ashley, Elizabeth A., et al.
Publicado: (2018)

Current and Future Treatment Landscape for Idiopathic Pulmonary Fibrosis
por: Bonella, Francesco, et al.
Publicado: (2023)

Drugs in Development for Hepatitis B
por: Dawood, Altaf, et al.
Publicado: (2017)

Utilisation and safety of catheter ablation of atrial fibrillation in public and private sector hospitals
por: Ngo, Linh, et al.
Publicado: (2021)

Recent Advances in Antiarrhythmic Drug Therapy
por: Saljic, Arnela, et al.
Publicado: (2023)

The New Era of Drug Therapy for Obesity: The Evidence and the Expectations
por: Jones, Ben J., et al.
Publicado: (2015)

Management of Hypertension in the Elderly and Frail Patient
por: Guasti, Luigina, et al.
Publicado: (2022)

Drug Repurposing to Target Neuroinflammation and Sensory Neuron-Dependent Pain
por: Sisignano, Marco, et al.
Publicado: (2022)

Drug Treatment of Hypercholesterolemia in Older Adults: Focus on Newer Agents
por: Stoll, Felicitas, et al.
Publicado: (2022)

Nutrition as a modifiable factor in the onset and progression of pulmonary function impairment in COPD: a systematic review
por: van Iersel, Lieke E J, et al.
Publicado: (2022)

Auranofin: Repurposing an Old Drug for a Golden New Age
por: Roder, Christine, et al.
Publicado: (2015)

Incorporating Pharmacometrics into Pharmacoeconomic Models: Applications from Drug Development
por: Srinivasan, Meenakshi, et al.
Publicado: (2020)

The Challenging Pharmacokinetics of Mitotane: An Old Drug in Need of New Packaging
por: Haider, Malik Salman, et al.
Publicado: (2021)

Targeted Small Molecules for Systemic Lupus Erythematosus: Drugs in the Pipeline
por: Mok, Chi Chiu
Publicado: (2023)

Degradability of chitosan micro/nanoparticles for pulmonary drug delivery
por: Islam, Nazrul, et al.
Publicado: (2019)

Institutional Variation in 30‐Day Complications Following Catheter Ablation of Atrial Fibrillation
por: Ngo, Linh, et al.
Publicado: (2022)

Diabetes of the Exocrine Pancreas: Implications for Pharmacological Management
por: Goodarzi, Mark O., et al.
Publicado: (2023)

Newly Approved and Investigational Drugs for Motor Symptom Control in Parkinson's Disease
por: Di Luca, Daniel Garbin, et al.
Publicado: (2022)

Overview of Current Drugs and Molecules in Development for Spinal Muscular Atrophy Therapy
por: Shorrock, Hannah K., et al.
Publicado: (2018)

The Impact of the COVID-19 “Infodemic” on Drug-Utilization Behaviors: Implications for Pharmacovigilance
por: Tuccori, Marco, et al.
Publicado: (2020)

The Use of Antiallergic and Antiasthmatic Drugs in Viral Infections of the Upper Respiratory Tract
por: Åberg, Nils
Publicado: (2012)

Established and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention
por: Michaeli, Daniel Tobias, et al.
Publicado: (2023)

Ongoing Developments and Clinical Progress in Drug-Loaded Red Blood Cell Technologies
por: Rossi, Luigia, et al.
Publicado: (2020)

Overview of Causality Assessment for Drug-Induced Liver Injury (DILI) in Clinical Trials
por: Hey-Hadavi, Juliana, et al.
Publicado: (2021)

An Update on the Management of Childhood-Onset Systemic Lupus Erythematosus
por: Trindade, Vitor Cavalcanti, et al.
Publicado: (2021)

Emerging Options for the Prevention and Management of Clostridioides difficile Infection
por: Gonzales-Luna, Anne J., et al.
Publicado: (2023)

New Pharmacological Approaches to the Management of Premenstrual Dysphoric Disorder
por: Sundström-Poromaa, Inger, et al.
Publicado: (2023)

Evaluation of Drug Prescribing Habits in a Postgraduate Teaching Set-up in Saudi Arabia
por: AI-Dawood, Kasim
Publicado: (1995)

How the Global COVID-19 Pandemic Brought Drug and Vaccine Development into the Public Mainstream
por: Witek, Theodore J.
Publicado: (2021)

Combined Angiotensin Receptor Modulation in the Management of Cardio-Metabolic Disorders
por: Paulis, Ludovit, et al.
Publicado: (2015)

Managing Antiphospholipid Syndrome in Children and Adolescents: Current and Future Prospects
por: Islabão, Aline Garcia, et al.
Publicado: (2021)

Clinical Impact of Checkpoint Inhibitors as Novel Cancer Therapies
por: Shih, Kent, et al.
Publicado: (2014)

Rational Use of Tocilizumab in the Treatment of Novel Coronavirus Pneumonia
por: Zhang, Shengyu, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_dru6fk1efd8f46k2jh3kn2u2dn